ea0056oc10.2 | Cardiovascular aspects of endocrine diseases | ECE2018
Nasiri-Ansari Narjes
, Dimitriadis Georgios K.
, Agorogiannis George
, Perrea Despina
, Daikos George
, Papavassiliou Athanasios G.
, Kaltsas Gregory
, Randeva Harpal S.
, Kassi Eva
Introduction: Treatment with sodium glucose co-transporter2(SGLT2) inhibitors was found to reduce the incidence of cardiovascular events in diabetic patients.Herein, we investigated the effects of long-term treatment with canagliflozin on atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice as well as on biochemical and immunohistochemical markers related to atherosclerosis.Methods: At 4 weeks of ...